Impact of aspirin on takotsubo syndrome: a propensity score-based analysis of the InterTAK Registry

  • Fabrizio D'Ascenzo
  • Sebastiano Gili
  • Maurizio Bertaina
  • Mario Iannaccone
  • Victoria L Cammann
  • Davide Di Vece
  • Ken Kato
  • Andrea Saglietto
  • Konrad A Szawan
  • Antonio H Frangieh
  • Beatrice Boffini
  • Margherita Annaratone
  • Annahita Sarcon
  • Rena A Levinson
  • Jennifer Franke
  • L Christian Napp
  • Milosz Jaguszewski
  • Michel Noutsias
  • Thomas Münzel
  • Maike Knorr
  • Susanne Heiner
  • Hugo A Katus
  • Christof Burgdorf
  • Heribert Schunkert
  • Holger Thiele
  • Johann Bauersachs
  • Carsten Tschöpe
  • Burkert M Pieske
  • Lawrence Rajan
  • Guido Michels
  • Roman Pfister
  • Alessandro Cuneo
  • Claudius Jacobshagen
  • Gerd Hasenfuß
  • Mahir Karakas
  • Wolfgang Koenig
  • Wolfgang Rottbauer
  • Samir M Said
  • Ruediger C Braun-Dullaeus
  • Adrian Banning
  • Florim Cuculi
  • Richard Kobza
  • Thomas A Fischer
  • Tuija Vasankari
  • K E Juhani Airaksinen
  • Grzegorz Opolski
  • Rafal Dworakowski
  • Philip MacCarthy
  • Christoph Kaiser
  • Stefan Osswald
  • Leonarda Galiuto
  • Filippo Crea
  • Wolfgang Dichtl
  • Wolfgang M Franz
  • Klaus Empen
  • Stephan B Felix
  • Clément Delmas
  • Olivier Lairez
  • Ibrahim El-Battrawy
  • Ibrahim Akin
  • Martin Borggrefe
  • John D Horowitz
  • Martin Kozel
  • Petr Tousek
  • Petr Widimský
  • Ekaterina Gilyarova
  • Alexandra Shilova
  • Mikhail Gilyarov
  • Giuseppe Biondi-Zoccai
  • David E Winchester
  • Christian Ukena
  • Michael Neuhaus
  • Jeroen J Bax
  • Abhiram Prasad
  • Carlo Di Mario
  • Michael Böhm
  • Mauro Gasparini
  • Frank Ruschitzka
  • Eduardo Bossone
  • Rodolfo Citro
  • Mauro Rinaldi
  • Gaetano Maria De Ferrari
  • Thomas Lüscher
  • Jelena R Ghadri
  • Christian Templin

Related Research units

Abstract

AIMS: The aim of the present study was to investigate the impact of aspirin on prognosis in takotsubo syndrome (TTS).

METHODS AND RESULTS: Patients from the International Takotsubo (InterTAK) Registry were categorized into two groups based on aspirin prescription at discharge. A comparison of clinical outcomes between groups was performed using an adjusted analysis with propensity score (PS) stratification; results from the unadjusted analysis were also reported to note the effect of the PS adjustment. Major adverse cardiac and cerebrovascular events (MACCE: a composite of death, myocardial infarction, TTS recurrence, stroke or transient ischaemic attack) were assessed at 30-day and 5-year follow-up. A total of 1533 TTS patients with known status regarding aspirin prescription at discharge were included. According to the adjusted analysis based on PS stratification, aspirin was not associated with a lower hazard of MACCE at 30-day [hazard ratio (HR) 1.24, 95% confidence interval (CI) 0.50-3.04, P = 0.64] or 5-year follow-up (HR 1.11, 95% CI 0.78-1.58, P = 0.58). These results were confirmed by sensitivity analyses performed with alternative PS-based methods, i.e. covariate adjustment and inverse probability of treatment weighting.

CONCLUSION: In the present study, no association was found between aspirin use in TTS patients and a reduced risk of MACCE at 30-day and 5-year follow-up. These findings should be confirmed in adequately powered randomized controlled trials. ClinicalTrials.gov Identifier: NCT01947621.

Bibliographical data

Original languageEnglish
ISSN1388-9842
DOIs
Publication statusPublished - 01.02.2020

Comment Deanary

© 2019 The Authors. European Journal of Heart Failure © 2019 European Society of Cardiology.

PubMed 31863563